Regeneron: Data Confirm Drug's Success In Aiding Gout Treatment - Wall Street Journal

Forbes (blog)

Regeneron: Data Confirm Drug's Success In Aiding Gout Treatment Wall Street Journal In June, the company reported the results of the Pre-surge 1 trial, but also another study that showed that Arcalyst failed to significantly relieve pain in patients already suffering an acute attack of the condition. ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second ...PR Newswire (press release) all 34 news articles »

Diagnosis and Treatment of Gout Reviewed - Medscape

Diagnosis and Treatment of Gout Reviewed Medscape Hyperuricemia may not be present during acute gout attacks and therefore may not be useful for diagnosis. Diagnosis of acute gout is largely clinical based on a characteristic presentation with rapid (within 24 hours) development of severe pain, ...

Seniors Group Asks Medicare Part-D Plans To Provide Affordable Gout Medication ... - Medical News Today (press release)

Seniors Group Asks Medicare Part-D Plans To Provide Affordable Gout Medication ... Medical News Today (press release) "It is unjust to force patients to suffer through often excruciatingly-painful acute gout flare-ups despite the fact that they were promised affordable coverage for their medications." The FDA's "Unapproved Drugs Initiative" calls for the removal of ...

Medicis shares gain on generic delay. PDL BioPharma settles with Novartis ... - BioMedReports (subscription)

Medicis shares gain on generic delay. PDL BioPharma settles with Novartis ... BioMedReports (subscription) The primary endpoint was the number of gout flares per patient over the 16-week treatment period. Santarus, Inc. (NASDAQ:SNTS) and biotech company Pharming Group NV (NYSE Euronext:PHARM) today announced the receipt of a "refusal to file" letter from ... and more »